Our findings indicate that treatment with the dual GLP-1 and glucagon receptor agonist cotadutide improves metabolic and functional parameters in the liver compared with placebo and liraglutide in patients with T2DM and overweight or obesity. This evidence concerns the gene GCG and type 2 diabetes mellitus.